Cargando…

Risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy

AIM: Patients with lipodystrophy are at high risk for chronic complications of diabetes. Recently, we have reported 18 diabetic foot ulcer episodes in 9 subjects with lipodystrophy. This current study aims to determine risk factors associated with foot ulcer development in this rare disease populati...

Descripción completa

Detalles Bibliográficos
Autores principales: Saydam, O, Ozgen Saydam, B, Adiyaman, SC, Sonmez Ince, M, Eren, MA, Keskin, FE, Bilen, H, Dagdeviren, M, Kaya, S, Akinci, G, Balci, A, Altay, C, Bayraktar, F, Oral, EA, Akinci, B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485489/
https://www.ncbi.nlm.nih.gov/pubmed/34593051
http://dx.doi.org/10.1186/s40842-021-00132-9
_version_ 1784577546145234944
author Saydam, O
Ozgen Saydam, B
Adiyaman, SC
Sonmez Ince, M
Eren, MA
Keskin, FE
Bilen, H
Dagdeviren, M
Kaya, S
Akinci, G
Balci, A
Altay, C
Bayraktar, F
Oral, EA
Akinci, B
author_facet Saydam, O
Ozgen Saydam, B
Adiyaman, SC
Sonmez Ince, M
Eren, MA
Keskin, FE
Bilen, H
Dagdeviren, M
Kaya, S
Akinci, G
Balci, A
Altay, C
Bayraktar, F
Oral, EA
Akinci, B
author_sort Saydam, O
collection PubMed
description AIM: Patients with lipodystrophy are at high risk for chronic complications of diabetes. Recently, we have reported 18 diabetic foot ulcer episodes in 9 subjects with lipodystrophy. This current study aims to determine risk factors associated with foot ulcer development in this rare disease population. METHODS: Ninety metreleptin naïve patients with diabetes registered in our national lipodystrophy database were included in this observational retrospective cohort study (9 with and 81 without foot ulcers). RESULTS: Patients with lipodystrophy developing foot ulcers had longer diabetes duration (p = 0.007), longer time since lipodystrophy diagnosis (p = 0.008), and higher HbA1c levels (p = 0.041). Insulin use was more prevalent (p = 0.003). The time from diagnosis of diabetes to first foot ulcer was shorter for patients with generalized lipodystrophy compared to partial lipodystrophy (p = 0.036). Retinopathy (p < 0.001), neuropathy (p < 0.001), peripheral artery disease (p = 0.001), and kidney failure (p = 0.003) were more commonly detected in patients with foot ulcers. Patients with foot ulcers tended to have lower leptin levels (p = 0.052). Multiple logistic regression estimated significant associations between foot ulcers and generalized lipodystrophy (OR: 40.81, 95% CI: 3.31–503.93, p = 0.004), long-term diabetes (≥ 15 years; OR: 27.07, 95% CI: 2.97–246.39, p = 0.003), and decreased eGFR (OR: 13.35, 95% CI: 1.96–90.67, p = 0.008). CONCLUSIONS: Our study identified several clinical factors associated with foot ulceration among patients with lipodystrophy and diabetes. Preventive measures and effective treatment of metabolic consequences of lipodystrophy are essential to prevent the occurrence of foot ulcers in these high-risk individuals.
format Online
Article
Text
id pubmed-8485489
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84854892021-10-04 Risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy Saydam, O Ozgen Saydam, B Adiyaman, SC Sonmez Ince, M Eren, MA Keskin, FE Bilen, H Dagdeviren, M Kaya, S Akinci, G Balci, A Altay, C Bayraktar, F Oral, EA Akinci, B Clin Diabetes Endocrinol Research Article AIM: Patients with lipodystrophy are at high risk for chronic complications of diabetes. Recently, we have reported 18 diabetic foot ulcer episodes in 9 subjects with lipodystrophy. This current study aims to determine risk factors associated with foot ulcer development in this rare disease population. METHODS: Ninety metreleptin naïve patients with diabetes registered in our national lipodystrophy database were included in this observational retrospective cohort study (9 with and 81 without foot ulcers). RESULTS: Patients with lipodystrophy developing foot ulcers had longer diabetes duration (p = 0.007), longer time since lipodystrophy diagnosis (p = 0.008), and higher HbA1c levels (p = 0.041). Insulin use was more prevalent (p = 0.003). The time from diagnosis of diabetes to first foot ulcer was shorter for patients with generalized lipodystrophy compared to partial lipodystrophy (p = 0.036). Retinopathy (p < 0.001), neuropathy (p < 0.001), peripheral artery disease (p = 0.001), and kidney failure (p = 0.003) were more commonly detected in patients with foot ulcers. Patients with foot ulcers tended to have lower leptin levels (p = 0.052). Multiple logistic regression estimated significant associations between foot ulcers and generalized lipodystrophy (OR: 40.81, 95% CI: 3.31–503.93, p = 0.004), long-term diabetes (≥ 15 years; OR: 27.07, 95% CI: 2.97–246.39, p = 0.003), and decreased eGFR (OR: 13.35, 95% CI: 1.96–90.67, p = 0.008). CONCLUSIONS: Our study identified several clinical factors associated with foot ulceration among patients with lipodystrophy and diabetes. Preventive measures and effective treatment of metabolic consequences of lipodystrophy are essential to prevent the occurrence of foot ulcers in these high-risk individuals. BioMed Central 2021-10-01 /pmc/articles/PMC8485489/ /pubmed/34593051 http://dx.doi.org/10.1186/s40842-021-00132-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Saydam, O
Ozgen Saydam, B
Adiyaman, SC
Sonmez Ince, M
Eren, MA
Keskin, FE
Bilen, H
Dagdeviren, M
Kaya, S
Akinci, G
Balci, A
Altay, C
Bayraktar, F
Oral, EA
Akinci, B
Risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy
title Risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy
title_full Risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy
title_fullStr Risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy
title_full_unstemmed Risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy
title_short Risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy
title_sort risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485489/
https://www.ncbi.nlm.nih.gov/pubmed/34593051
http://dx.doi.org/10.1186/s40842-021-00132-9
work_keys_str_mv AT saydamo riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy
AT ozgensaydamb riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy
AT adiyamansc riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy
AT sonmezincem riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy
AT erenma riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy
AT keskinfe riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy
AT bilenh riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy
AT dagdevirenm riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy
AT kayas riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy
AT akincig riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy
AT balcia riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy
AT altayc riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy
AT bayraktarf riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy
AT oralea riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy
AT akincib riskfactorsfordiabeticfootulcersinmetreleptinnaivepatientswithlipodystrophy